Bayer expands discovery deal with PPD spinout X-Chem


Bayer has been testing out its relationship with X-Chem since 2012. Now, after already having licensed two programs from it, the pharma has upped the ante with a bigger discovery deal.

The new deal extends Bayer access to X-Chem’s DEX technology that’s based on DNA-encoded libraries of small molecules.  It includes an undisclosed upfront payment and R&D funding, in addition to up to $528 million in preclinical, clinical and regulatory milestone payments.

"We have identified the DEX platform as a highly valuable extension for our drug discovery efforts. We are looking forward to working with X-Chem on some of our highest-priority targets," said Andreas Busch, who is a member of the executive committee of Bayer's Pharmaceuticals Division and Head of Drug Discovery, in a statement.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

The two programs that Bayer has already licensed from X-Chem are for a series of small molecules targeting complex structures such as protein/protein interactions. Its drug discovery is based on a library generated via iterative combinatorial synthesis of small molecules tethered to DNA tags that record each molecule’s synthetic history.

X-Chem was owned by contract research organization Pharmaceutical Product Development (PPD), which spun it back out as an independent company early this year. It was founded in 2009 by management from micro-cap Praecis Pharmaceuticals, which sold to GlaxoSmithKline ($GSK) for $55 million in 2007. In 2010, X-Chem partnered with PPD in a deal that included a purchase option, which PPD exercised in the fall of 2014 to buy the entire company.

It also has deals with several other biopharmas including Roche ($ROG), AstraZeneca ($AZN), Pfizer ($PFE), Sanofi ($SNY), Janssen ($JNJ) and Alexion ($ALXN).

"X-Chem is making significant inroads toward the discovery of small molecule drug candidates using its ultra-large screening library,” said X-Chem CEO Rick Wagner. “With multiple successes across our partnerships, the DEX platform has been broadly validated to deliver novel chemical entities against a wide array of targets, including difficult targets."

- here is the release

Related Articles:
PPD's X-Chem strikes another deal with Bayer
PPD bets on drug discovery with X-Chem deal
PPD's in-house biotech pairs up with J&J


Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.